Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas
| Autor: | Bolette L. Caron, Ellen D. Remstein, Erik C. Thorland, Mark E. Law, William R. Macon, Ahmet Dogan, David X. Sun, Andrew L. Feldman, Ayoma D. Attygalle, Paul J. Kurtin, Stephanie R. Fink, Karen L. Grogg, William G. Morice, Anne J. Novak, Julie A. Vrana |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research Adolescent T cell Blotting Western Syk Biology environment and public health Article Translocation Genetic Immunophenotyping Immunoenzyme Techniques Western blot hemic and lymphatic diseases medicine Humans Syk Kinase Tyrosine Phosphorylation Child In Situ Hybridization Fluorescence Aged Aged 80 and over medicine.diagnostic_test Intracellular Signaling Peptides and Proteins Lymphoma T-Cell Peripheral hemic and immune systems Hematology Middle Aged Protein-Tyrosine Kinases Flow Cytometry Lymphoma T-Cell Cutaneous Blot Lymphoma Extranodal NK-T-Cell enzymes and coenzymes (carbohydrates) medicine.anatomical_structure Oncology Child Preschool Cancer research Immunohistochemistry Chromosomes Human Pair 5 Lymphoma Large-Cell Anaplastic Female biological phenomena cell phenomena and immunity Chromosomes Human Pair 9 Tyrosine kinase |
| Popis: | Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n=6) and flow cytometry on cell suspensions (n=4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|